Diarrhea - Pipeline Review, H1 2017
ReportsWeb.com has announced the addition of the “Diarrhea - Pipeline Review, H1 2017” this report provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.
(EMAILWIRE.COM, June 10, 2017 ) Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 15, 2, 21 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.
Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/diarrhea-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689411/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
A. Menarini Industrie Farmaceutiche Riunite Srl
Actelion Ltd
Aegis Therapeutics LLC
Akthelia Pharmaceuticals Ltd
Albireo Pharma Inc
AmpliPhi Biosciences Corp
Anatara Lifesciences Limited
Ardelyx Inc
Assembly Biosciences Inc
AzurRx BioPharma Inc
Bharat Biotech International Ltd
CinRx Pharma LLC
Codagenix Inc
Cosmo Pharmaceuticals NV
DesignMedix Inc
DiscoveryBiomed Inc
Genextra Spa
GlaxoSmithKline Plc
GP Pharm SA
Miyarisan Pharmaceutical Company Ltd
Mucosis BV
Napo Pharmaceuticals Inc
Nippon Shinyaku Co Ltd
Novartis AG
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Recce Ltd
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Sigmoid Pharma Ltd
Summit Therapeutics Plc
Synthetic Biologics Inc
Syntiron LLC
Tasly Pharmaceutical Group Co Ltd
Wuhan Institute of Biological Products Co Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689411/discount
List of Tables
Number of Products under Development for Diarrhea, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
Diarrhea - Pipeline by Actelion Ltd, H1 2017
Diarrhea - Pipeline by Aegis Therapeutics LLC, H1 2017
Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
Diarrhea - Pipeline by Albireo Pharma Inc, H1 2017
Diarrhea - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Diarrhea - Pipeline by Anatara Lifesciences Limited, H1 2017
Diarrhea - Pipeline by Ardelyx Inc, H1 2017
Diarrhea - Pipeline by Assembly Biosciences Inc, H1 2017
Diarrhea - Pipeline by AzurRx BioPharma Inc, H1 2017
Diarrhea - Pipeline by Bharat Biotech International Ltd, H1 2017
Diarrhea - Pipeline by CinRx Pharma LLC, H1 2017
Diarrhea - Pipeline by Codagenix Inc, H1 2017
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
Diarrhea - Pipeline by DesignMedix Inc, H1 2017
Diarrhea - Pipeline by DiscoveryBiomed Inc, H1 2017
Diarrhea - Pipeline by Genextra Spa, H1 2017
Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2017
Diarrhea - Pipeline by GP Pharm SA, H1 2017
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
Diarrhea - Pipeline by Mucosis BV, H1 2017
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H1 2017
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Diarrhea - Pipeline by Novartis AG, H1 2017
Diarrhea - Pipeline by Pfizer Inc, H1 2017
Diarrhea - Pipeline by Prokarium Ltd, H1 2017
Diarrhea - Pipeline by Rebiotix Inc, H1 2017
Diarrhea - Pipeline by Recce Ltd, H1 2017
Diarrhea - Pipeline by RedHill Biopharma Ltd, H1 2017
Diarrhea - Pipeline by RxBio Inc, H1 2017
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2017
Diarrhea - Pipeline by Sigmoid Pharma Ltd, H1 2017
Diarrhea - Pipeline by Summit Therapeutics Plc, H1 2017
Diarrhea - Pipeline by Synthetic Biologics Inc, H1 2017
Diarrhea - Pipeline by Syntiron LLC, H1 2017
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2017
Diarrhea - Dormant Projects, H1 2017
Diarrhea - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diarrhea - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689411/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 15, 2, 21 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.
Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/diarrhea-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689411/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
A. Menarini Industrie Farmaceutiche Riunite Srl
Actelion Ltd
Aegis Therapeutics LLC
Akthelia Pharmaceuticals Ltd
Albireo Pharma Inc
AmpliPhi Biosciences Corp
Anatara Lifesciences Limited
Ardelyx Inc
Assembly Biosciences Inc
AzurRx BioPharma Inc
Bharat Biotech International Ltd
CinRx Pharma LLC
Codagenix Inc
Cosmo Pharmaceuticals NV
DesignMedix Inc
DiscoveryBiomed Inc
Genextra Spa
GlaxoSmithKline Plc
GP Pharm SA
Miyarisan Pharmaceutical Company Ltd
Mucosis BV
Napo Pharmaceuticals Inc
Nippon Shinyaku Co Ltd
Novartis AG
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Recce Ltd
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Sigmoid Pharma Ltd
Summit Therapeutics Plc
Synthetic Biologics Inc
Syntiron LLC
Tasly Pharmaceutical Group Co Ltd
Wuhan Institute of Biological Products Co Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689411/discount
List of Tables
Number of Products under Development for Diarrhea, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
Diarrhea - Pipeline by Actelion Ltd, H1 2017
Diarrhea - Pipeline by Aegis Therapeutics LLC, H1 2017
Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
Diarrhea - Pipeline by Albireo Pharma Inc, H1 2017
Diarrhea - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Diarrhea - Pipeline by Anatara Lifesciences Limited, H1 2017
Diarrhea - Pipeline by Ardelyx Inc, H1 2017
Diarrhea - Pipeline by Assembly Biosciences Inc, H1 2017
Diarrhea - Pipeline by AzurRx BioPharma Inc, H1 2017
Diarrhea - Pipeline by Bharat Biotech International Ltd, H1 2017
Diarrhea - Pipeline by CinRx Pharma LLC, H1 2017
Diarrhea - Pipeline by Codagenix Inc, H1 2017
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
Diarrhea - Pipeline by DesignMedix Inc, H1 2017
Diarrhea - Pipeline by DiscoveryBiomed Inc, H1 2017
Diarrhea - Pipeline by Genextra Spa, H1 2017
Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2017
Diarrhea - Pipeline by GP Pharm SA, H1 2017
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
Diarrhea - Pipeline by Mucosis BV, H1 2017
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H1 2017
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Diarrhea - Pipeline by Novartis AG, H1 2017
Diarrhea - Pipeline by Pfizer Inc, H1 2017
Diarrhea - Pipeline by Prokarium Ltd, H1 2017
Diarrhea - Pipeline by Rebiotix Inc, H1 2017
Diarrhea - Pipeline by Recce Ltd, H1 2017
Diarrhea - Pipeline by RedHill Biopharma Ltd, H1 2017
Diarrhea - Pipeline by RxBio Inc, H1 2017
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2017
Diarrhea - Pipeline by Sigmoid Pharma Ltd, H1 2017
Diarrhea - Pipeline by Summit Therapeutics Plc, H1 2017
Diarrhea - Pipeline by Synthetic Biologics Inc, H1 2017
Diarrhea - Pipeline by Syntiron LLC, H1 2017
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2017
Diarrhea - Dormant Projects, H1 2017
Diarrhea - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diarrhea - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689411/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results